MX2024002102A - Partículas coloidales modificadas para usarse en el tratamiento de hemofilia a. - Google Patents

Partículas coloidales modificadas para usarse en el tratamiento de hemofilia a.

Info

Publication number
MX2024002102A
MX2024002102A MX2024002102A MX2024002102A MX2024002102A MX 2024002102 A MX2024002102 A MX 2024002102A MX 2024002102 A MX2024002102 A MX 2024002102A MX 2024002102 A MX2024002102 A MX 2024002102A MX 2024002102 A MX2024002102 A MX 2024002102A
Authority
MX
Mexico
Prior art keywords
haemophilia
colloidal particles
treatment
modified colloidal
antibody inhibitors
Prior art date
Application number
MX2024002102A
Other languages
English (en)
Inventor
Richard Wolf-Garraway
Edward Tuddenham
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of MX2024002102A publication Critical patent/MX2024002102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al uso de partículas coloidales para el tratamiento de la hemofilia A en pacientes con anticuerpos inhibidores o con antecedentes de desarrollar anticuerpos inhibidores del Factor VIII (FVIII). La invención también se refiere a métodos, kits y formas de dosificación que comprenden partículas coloidales para tratar la hemofilia A en pacientes con inhibidores de anticuerpos o con antecedentes de desarrollar inhibidores de anticuerpos del Factor VIII (FVIII).
MX2024002102A 2021-08-17 2022-08-17 Partículas coloidales modificadas para usarse en el tratamiento de hemofilia a. MX2024002102A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2111757.7A GB202111757D0 (en) 2021-08-17 2021-08-17 Modified colloidal particles for use in the treatment of haemophilia A
PCT/EP2022/073001 WO2023021109A1 (en) 2021-08-17 2022-08-17 Modified colloidal particles for use in the treatment of haemophilia a

Publications (1)

Publication Number Publication Date
MX2024002102A true MX2024002102A (es) 2024-05-10

Family

ID=77859947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002102A MX2024002102A (es) 2021-08-17 2022-08-17 Partículas coloidales modificadas para usarse en el tratamiento de hemofilia a.

Country Status (10)

Country Link
EP (1) EP4387595A1 (es)
JP (1) JP2024532163A (es)
KR (1) KR20240042134A (es)
CN (1) CN118119378A (es)
AU (1) AU2022329447A1 (es)
CA (1) CA3227154A1 (es)
GB (2) GB202111757D0 (es)
IL (1) IL310768A (es)
MX (1) MX2024002102A (es)
WO (1) WO2023021109A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69418334T2 (de) 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
KR100758158B1 (ko) 1999-07-14 2007-09-12 알자 코포레이션 중성 지질중합체 및 그를 함유하는 리포솜 조성물
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
GB201518171D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine

Also Published As

Publication number Publication date
CN118119378A (zh) 2024-05-31
IL310768A (en) 2024-04-01
GB202403662D0 (en) 2024-05-01
CA3227154A1 (en) 2023-02-23
AU2022329447A1 (en) 2024-03-14
GB2625660A (en) 2024-06-26
WO2023021109A1 (en) 2023-02-23
KR20240042134A (ko) 2024-04-01
GB202111757D0 (en) 2021-09-29
EP4387595A1 (en) 2024-06-26
JP2024532163A (ja) 2024-09-05

Similar Documents

Publication Publication Date Title
MX2024000054A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
NZ592786A (en) Methods and compositions for treating complement-associated disorders using eculizumab
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
MX2022014422A (es) Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos.
MX2021006954A (es) Terapia combinada contra el virus de la hepatitis b (vhb).
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
ATE394097T1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
ZA202106769B (en) Treatment of ciliopathies
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
ATE531366T1 (de) Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
MX2020007431A (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto oseo.
MX2024002102A (es) Partículas coloidales modificadas para usarse en el tratamiento de hemofilia a.
EA202192865A1 (ru) Лечение головной боли с использованием антител к cgrp
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2024002100A (es) Partículas coloidales modificadas para uso en el tratamiento de la hemofilia a.
MX2023004913A (es) Uso de un antagonista de il-18 para el tratamiento y/o la prevencion de dermatitis atopica o una afeccion relacionada.
MX2023003723A (es) Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
MX2024002103A (es) Partículas coloidales modificadas para uso en el tratamiento de la hemofilia a.